The electrophysiology catheter market in Asia Pacific is expected to grow from US$ 918.81 million in 2021 to US$ 1,677.80 million by 2028; it is estimated to grow at a CAGR of 9.0% from 2021 to 2028.
A report by NCBI states that, nowadays, there is a strong focus on robotic systems developed to manipulate and position electrophysiology catheters. For example, Catheter Robotics EP catheter-based remote catheter manipulation system (RCMS) appears safe and efficient in directing EP catheters to intracardiac sites and achieving pacing thresholds and electrograms equivalent to manually placed catheters. Apart from that, intra-operative magnetic resonance imaging (MRI) improves soft-tissue visualization during catheter manipulation, reducing complications, and readily visualizing the physiological change. If provided with high-quality MR images, it assists in cardiac navigation and robotic catheterization, enhancing the safety and efficiency of EP catheterization. Currently, there is no MR-compatible commercialized robotic system available in the market. However, adopting such an advanced robotic system in the future can benefit electro-physiologists in performing better while conducting cardiac ablation procedures, consequently improving the safety of catheter navigation during the EP procedure, which is further anticipated to drive the market in Asia Pacific.
As per the Worldometer data as of March 2021, China, Japan, India, South Korea, and Australia have reported 90,066; 448,688; 11,438,734; 96,849; and 29,151 COVID-19 cases, respectively. The shrinking economies of many countries are limiting the progress of sectors such as pharmaceuticals. The extended pandemic period, combined with concerns about economic recovery, further harm the pharmaceutical business in Asia Pacific. A few research institutes in this region are actively participating in research targeted at the management of COVID-19. The major traction toward the management of COVID-19 has hampered the detection and treatment of noncommunicable diseases. It led to a significant and abrupt reduction in cardiovascular diagnostic testing across APAC.
Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Electrophysiology Catheter Market Segmentation
Asia Pacific Electrophysiology Catheter Market – By Product Type
-
Electrophysiology Ablation Catheters
- Cryoablation Electrophysiology Catheter
- Radiofrequency Ablation Catheters
- Microwave Ablation Systems
- Laser Ablation Systems
-
Electrophysiology Diagnostic Catheters
- Conventional Electrophysiology Diagnostic Catheters
- Advanced Electrophysiology Diagnostic Catheters
- Ultrasound Electrophysiology Diagnostic Catheters
Asia Pacific Electrophysiology Catheter Market – By Application
- Diagnosis and Monitoring
- Treatment of Cardiac Arrhythmias
- Imaging and Mapping
Asia Pacific Electrophysiology Catheter Market – By End User
- Hospitals
- Ambulatory Surgical Centers
- Cardiac Catheterization Labs
Asia Pacific Electrophysiology Catheter Market– By Country
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
Asia Pacific Electrophysiology Catheter Market-Companies Mentioned
- Abbott
- APT Medical Inc.
- Biosense Webster (Johnson and Johnson Services, Inc.)
- Biotronik, Inc.
- Boston Scientific Corporation
- Medtronic
- CathRx Ltd
- MicroPort Scientific Corporation
- Stryker Corporation
- Transonic Systems Inc.
Asia Pacific Electrophysiology Catheter Market Strategic Insights
Asia Pacific Electrophysiology CatheterMarket Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 918.81 Million |
| Market Size by 2028 | US$ 1,677.80 Million |
| CAGR (2021 - 2028) | 9.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
Asia Pacific Electrophysiology Catheter Market Country and Regional Insights
